个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Efficacy and safety of abrocitinib in combination with topical therapy in adolescents from China with moderate-to-severe atopic dermatitis: A post hoc analysis of the JADE TEEN phase 3 trial

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Yao, Zhirong[1] ; Xu, Aie[2] ; He, Li[3] ; Ding, Yangfeng[4] ; Hu, Guohong[5] ; Vyas, Shefali[6] ; Wang, Bo[7] ; Luo, Xin[8] ; Li, Shiqi[9] ;
机构： [1]Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Shanghai, Peoples R China [2]Hangzhou Third Peoples Hosp, Hangzhou, Zhejiang, Peoples R China [3]Kunming Med Univ, Affiliated Hosp 1, Kunming, Yunnan, Peoples R China [4]Tongji Univ, Sch Med, Shanghai Skin Dis Hosp, Shanghai, Peoples R China [5]Dermatol Hosp Jiangxi Prov, Nanchang, Jiangxi, Peoples R China [6]Pfizer Inc, New York, NY USA [7]Pfizer Investment Co Ltd, Beijing, Peoples R China [8]Pfizer China R&D Co Ltd, Shanghai, Peoples R China [9]Pfizer PBG, Shanghai, Peoples R China
出处：
DOI： 10.1093/bjd/ljad498.027
ISSN：

关键词： abrocitinib adolescent atopic dermatitis China Janus kinase inhibitor

基金：
Editorial/medical writing support under the guidance of the authors was provided by Chantell Hayward, PharmD, at Apothecom, San Francisco, CA, USA, and was funded by Pfizer Inc., New York, NY, USA, in accordance with Good Publication Practice (GPP 2022) guidelines (Ann Intern Med. 2022; 10.7326/M22-1460). This study was sponsored by Pfizer Inc., New York, NY, USA.
语种：
外文
WOS：
中科院(CAS)分区：
出版当年[2025]版：
无
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 皮肤病学
JCR分区：
出版当年[2024]版：
无
最新[2023]版：
Q1 DERMATOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2024版] 出版当年五年平均 出版前一年[2023版]

第一作者：
第一作者机构： [1]Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Shanghai, Peoples R China
推荐引用方式(GB/T 7714)：
Yao Zhirong,Xu Aie,He Li,et al.Efficacy and safety of abrocitinib in combination with topical therapy in adolescents from China with moderate-to-severe atopic dermatitis: A post hoc analysis of the JADE TEEN phase 3 trial[J].BRITISH JOURNAL OF DERMATOLOGY.2024,190:II23-II24.doi:10.1093/bjd/ljad498.027.
APA：
Yao, Zhirong,Xu, Aie,He, Li,Ding, Yangfeng,Hu, Guohong...&Li, Shiqi.(2024).Efficacy and safety of abrocitinib in combination with topical therapy in adolescents from China with moderate-to-severe atopic dermatitis: A post hoc analysis of the JADE TEEN phase 3 trial.BRITISH JOURNAL OF DERMATOLOGY,190,
MLA：
Yao, Zhirong,et al."Efficacy and safety of abrocitinib in combination with topical therapy in adolescents from China with moderate-to-severe atopic dermatitis: A post hoc analysis of the JADE TEEN phase 3 trial".BRITISH JOURNAL OF DERMATOLOGY 190.(2024):II23-II24

相关文献

[1]Clinical Features of Adult/Adolescent Atopic Dermatitis and Chinese Criteria for Atopic Dermatitis [2]Atopic Dermatitis and Skin Cancer Risk: A Systematic Review [3]MiR-1294 suppresses ROS-dependent inflammatory response in atopic dermatitis via restraining STAT3/NF-κB pathway. [4]A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AK120 in Subjects With Atopic Dermatitis [5]JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis (JADE TEEN) [6]MiR-1294 suppresses ROS-dependent inflammatory response in atopic dermatitis via restraining STAT3/NF-κB pathway. [7]A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis [8]Crisaborole for Chinese and Japanese Subjects (≥2 Years of Age) With Mild to Moderate Atopic Dermatitis [9]特应性皮炎基层诊疗指南（2022年） [10]A Phase III Study to Evaluate the Efficacy and Safety of AK120 in Patients With Moderate to Severe Atopic Dermatitis

资源点击量：52537 今日访问量：0 总访问量：1562 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 昆明医科大学第一附属医院 技术支持：重庆聚合科技有限公司 地址：云南省昆明市西昌路295号(650032)